Author/	Study Design	Demographics	Outcome measures	Results					Methodological
Year	Study Dosign				Intervention	group		Control group	Comments
Venstrom J, 2003	Retrospective, controlled, multicenter cohort Transplant cohort: patients on UNOS/OPTN waiting list for a pancreas transplant (PA, PAK, SPK) from Jan 1, 1995 – Dec 31, 2000 who did receive a transplant Control cohort: patients on wait list who did not receive a transplant Analysis stratified by transplant type Exclusions: on wait list for multi-organ transplant other than SPK; creatinine >2 mg/dL at time of listing; listed for PA but eventually received SPK	Total N= 11,572 Transplanted N= 6595 PA= 378 PAK= 838 SPK= 5379 For the PA group: 40% men 10% ≥50 yrs old	Unadjusted wait list and post-transplant patient survival rates Mortality risk (hazard ratio-average risk for PA transplant patients compared to patients on wait list for comparable amount of time) assessed for 3 clinically distinct time periods in the transplant group: 0-90 days 91-365 days 366-1460 days	Baseline characteri	Mortality Risk 2.27 0.99 1.70 1.57 PA 96.5% 85.2% s: donor death ransplant (incl	= 361 lant and wait inguishable 95% CI 0.84-6.13 0.41-2.39 0.97-2.98 0.98-2.53	P value 0.11 0.99 0.06 0.06	Results presented for PA patients only: Wait list N= 311 Patient survival Wait list At 1 yr 97.6% At 4 yr 92.1%	Retrospective, observational nature of trial and small n are a negative. Use of a relevant control cohort is a plus. Uncertain if target population was studied- presume every patient added to UNOS/OPTN wait list met ADA criteria for PA Assessed patient survival/mortality risk. Short duration of study (i.e., 4 yrs post- transplant or on the wait list). Majority of study population was younger than 65 yrs. # lost to follow-up and # of cross-overs not
Gruessner R, 2004	Retrospective, controlled, multicenter cohort	For patients on the PA wait list:	Unadjusted wait list and post-transplant	Results presented for PA patients only: Transplant N= 647 Baseline characteristics of transplant v. wait list patients not stated Hazard ratio for Jan 1, 1995 – May 31, 2003 database:				N= 1207	reported. Retrospective, observational nature of
	on UNOS/IPTR waiting list for a pancreas transplant (PA, PAK, SPK) from Jan 1, 1995 – May 31, 2003 who did receive a transplant Transpla	Total N= 1207 42% men 38.8+/- 9.2 yrs 8.3% retransplant	Mortality hazard ratio assessed for 3 rs clinically distinct time periods in the transplant group:					Baseline characteristics of transplant v. wait list patients not stated	trial is a negative. Use of a relevant control cohort is a plus. Uncertain if target
		Transplanted N= 647		Time period (days) 0-90 91-365	Mortality 4.25 1.72	95% CI 1.68- 10.76 0.82-3.61	0.002 0.15		population was studied presume every patient added to UNOS/OPTN wait list met ADA criteria for PA
	Analysis stratified by transplant type			366 on Overall	0.15 0.66	0.08-0.29 0.39-1.12	0.0001 0.12		Assessed patient survival/mortality risk. Majority of study
	Patient with multiple listings at different transplant centers and/or who changed transplant center was counted only			Time period (days)	database Mortality		P value		population most likely younger than 65 yrs. 8% of patients were to receive a retransplant—

once A patient relisted was counted only once (and all wait times summed)	0-90 6.40 1.95-21.1 0.002 91-365 2.90 1.1-7.63 0.03 366 on 0.29 0.15-0.57 0.0003 Overall 1.45 0.83-2.55 0.19		i.e., presumably these patients were not excluded from cohort prior to analysis.
Exclusions: change in status from SPK/PAK/PA to KTA; listed for PA but	Patient survival PA At 1 yr 97% At 4 yr 90.5%	Patient survival Wait list At 1 yr 96.6% At 4 yr 87.3%	# lost to follow up not reported.
eventually received SPK; retransplant patients	Mortality risk factors: time of listing (1995-1998); use of depleting antibody induction therapy; graft failure	Mortality risk factors: time of listing (1995-1998); non-Caucasian (v. Caucasian)	

<u>Key</u>

CsA—cyclosporine A TAC—tacrolimus

DM—Diabetes mellitus

Pop—population

N/A—not applicable; not available

PA—pancreas transplant alone

SPK—simultaneous pancreas-kidney transplant

PAK—pancreas after kidney transplant

CI—confidence interval

KTA—kidney transplant alone